Hetacillin
A penicillin-class antibiotic that is a prodrug of ampicillin, rapidly converted to ampicillin in the body after absorption to exert its antibacterial effects. It was designed to improve oral bioavailability compared to early ampicillin formulations. Its spectrum of activity and uses are equivalent to those of ampicillin.
분자량
389.5000 g/mol
LogP
-0.60
TPSA
115.00 Ų
리핀스키 5의 법칙
통과
작용 기전
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
2D 구조
Cite this structure
Embed this structure
SMILES
CC1(C)S[C@@H]2[C@H](N3C(=O)[C@@H](c4ccccc4)NC3(C)C)C(=O)N2[C@H]1C(=O)O
InChI
InChI=1S/C19H23N3O4S/c1-18(2)13(17(25)26)21-15(24)12(16(21)27-18)22-14(23)11(20-19(22,3)4)10-8-6-5-7-9-10/h5-9,11-13,16,20H,1-4H3,(H,25,26)/t11-,12-,13+,16-/m1/s1
Molecular Formula
C19H23N3O4S
HBD / HBA
2 / 6
회전 가능 결합
3
무거운 원자
27
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
자주 묻는 질문
A penicillin-class antibiotic that is a prodrug of ampicillin, rapidly converted to ampicillin in the body after absorption to exert its antibacterial effects. It was designed to improve oral bioavailability compared to early ampicillin formulations. Its spectrum of activity and uses are equivalent to those of ampicillin.
Administered as an inactive precursor that is metabolically converted to its active form in the body. This prodrug design improves bioavailability, absorption, or targeted delivery compared to the active compound.
Yes, Hetacillin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201116. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 443387. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="hetacillin"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/hetacillin/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/hetacillin/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/hetacillin/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="hetacillin"></drugfyi-drug>